Global trends and the impact of chronic hepatitis B and C on disability‐adjusted life years. (4th July 2022)

• Record Type: Journal Article
• Authors: Veracruz, Nicolette; Gish, Robert G.; Cheung, Ramsey; Chitnis, Amit S.; Wong, Robert J.
• Is Part Of: Liver international. Volume 42:Number 10(2022)
• Page Start: 2145
• Page End: 2153
• Publication Date: 2022-07-04
• Subjects: chronic hepatitis B -- chronic hepatitis C -- global trends -- quality of life -- viral hepatitis; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.15347
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Background and Aims: Advances in hepatitis B virus (HBV) and hepatitis C virus (HCV) therapies have improved morbidity and mortality, but global disparities in viral hepatitis outcomes remain. We evaluate global trends in the impact of HBV and HCV on disability‐adjusted life years (DALYs). Methods: Using data from the 2010–2019 Global Burden of Diseases Study (GBD), overall all‐cause DALYs for patients with acute HBV or HCV, HBV‐ or HCV‐related cirrhosis, and HBV‐ or HCV‐related hepatocellular carcinoma (HCC) was calculated as the sum of years of life lost because of premature death and years lived with disability. DALYs were presented as age‐standardized rates per 100 000 population stratified by age and sex. Results: From 2010 to 2019, the overall global impact of HBV on DALYs per 100 000 decreased from 27.6 to 20.9 for acute HBV and 168.6 to 129.8 for HBV‐related cirrhosis but remained stable for HBV‐related HCC. The impact of HCV on DALYs per 100 000 decreased from 5.23 to 3.3 for acute HCV, 159.2 to 146.2 for HCV‐related cirrhosis, and 37.5 to 34.9 for HCV‐related HCC. We observed significant differences in the impact of HBV and HCV on DALYs when stratified by world regions. Conclusion: Decreases in HBV and HCV DALYs from 2010 to 2019 were observed. Disparities in DALY improvements across world regions suggest unequal access to viral hepatitis care and treatment. Achieving goals of viral hepatitis elimination will require enhanced prevention efforts and funding for high‐burden regions and regions that have not had substantial reductions in DALYs because of HBV and HCV.